USPTO serial 88490321
ELLIPSES PHARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 21, 2021
- Examiner
- OJEYEMI, ASHLEY CHRISTINE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ELLIPSES PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John C. Cain
John C. Cain Munck Wilson Mandala, LLP1330 Post Oak Boulevard, Suite 2850Houston, TX 77056United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumour necrosis factors; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer | ACTIVE | — |
| 010 | Medical and surgical apparatus and instruments, namely, instruments for diagnosing and treating cancer; medical analysis devices, namely, medical diagnostic devices for analyzing the presence or extent of cancer, and for monitoring cancer treatments, immunotherapy cancer treatments, radiation therapy cancer treatments, chemotherapy cancer treatments, radiotherapy cancer treatments, targeted cancer therapy treatments in the body, and for analyzing the efficacy of cancer treatments; medical imaging apparatus, namely, devices for cancer imaging; medical scanning apparatus namely, devices for scanning for cancer; apparatus for the diagnosis of cancer; apparatus for use in medical analysis for the diagnosis and treatment of cancer; cell counting units for medical diagnostic use, namely, electrical resistance cell counters, flow cytometers, and microscopic image analyzers; diagnostic apparatus for medical use for testing cancer cells; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer | ACTIVE | — |
| 042 | Medical and pharmacological research services; biological research, clinical research in the field of cancer and medical research; Providing an on-line network environment featuring technology that enables users to share data for drug and pharmaceutical research and development; Providing an on-line network environment featuring technology that enables users to share data in the field of the design, development and testing of drugs and pharmaceuticals; Providing scientific and technological services, namely, scientific research, analysis, and design relating to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer; design, development and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research in the field of cancer and oncology; expert advice relating to drug development, namely consulting services in the field of drug development; laboratory analysis in the field of oncology; computer hardware and software design and development in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; computer network services namely providing search engines for obtaining information on a global computer network in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software hosting services, namely, hosting software for use by others for use in relation to medical databases and information, in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software as a service (SAAS) namely, hosting software for use by others for use in relation to medical databases and information, in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; Information Technology (IT) consultancy, advisory and information services relating to a network of medical research professionals in the technology field of medical information networks and databases; scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology and cancer clinical trials; scientific research projects and studies in the fields of oncology and clinical trials research; conducting clinical trials for others; clinical research in the field of oncology; clinical research in the field of cancer treatments and pharmaceuticals; providing an online network that features technology that enables users to share data for clinical trials; conducting and compiling data for others for research purposes in the field of treatment, cure and prevention of cancer via an online computer network; development of measuring and testing methods in the field of medicine; evaluation of pharmaceutical drug development services of others to assure compliance with industry standards; pharmaceutical product evaluation; pharmaceutical research services; all of the aforesaid in relation to in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer | ACTIVE | — |
| 044 | Medical services; medical consultation services; cancer consultation and treatment services, namely, medical diagnosis and treatment of cancer; health care services; health screening services in field of cancer; cancer screening services; managed health care services; pharmaceutical services namely, pharmaceutical advice; providing online medical record services, namely maintaining personal medical history records and files; advisory and consultancy relating to all of the aforesaid; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Ellipses Pharma Ltd
- Other trademarks owned by Ellipses Pharma Ltd
- Other trademarks owned by Ellipses Pharma Ltd
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ELLIPSES PHARMA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 14, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| May 14, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 21, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 21, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 21, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 21, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 17, 2021 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Nov 17, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 3, 2021 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Nov 3, 2021 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| May 4, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 9, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 9, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 17, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 1, 2021 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Jan 29, 2021 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jan 28, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 15, 2021 | MREI | NOTICE OF REINSTATEMENT E-MAILED | — |
| Jan 8, 2021 | ZZZY | PREVIOUS ACTION COUNT WITHDRAWN | — |
| Jan 7, 2021 | RGIA | REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED | — |
| Jan 7, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 7, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 7, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 7, 2021 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 6, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 6, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 6, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 6, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 6, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 21, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 21, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 21, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 23, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 23, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 23, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 3, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 2, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 2, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 2, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 2, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 2, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Sep 5, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Aug 1, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jul 29, 2019 | ALIE | ASSIGNED TO LIE | — |
| Jul 23, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 6, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 29, 2019 | NWAP | NEW APPLICATION ENTERED | — |